Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 2/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 6/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3242716 | 1.00 | KMT2A (0.34) | KMT2AMEN1MAPTCYP2C19PLCG1 | |
| SCHEMBL3242715 | 1.00 | KMT2A (0.34) | KMT2AMEN1MAPTCYP2C19PLCG1 | |
| SCHEMBL7915963 | 1.00 | KMT2A (0.34) | KMT2AMEN1MAPTCYP2C19PLCG1 | |
| SCHEMBL7914680 | 0.90 | MEN1 (0.32) | KMT2AMEN1PLCG1ELANELMNA | |
| SCHEMBL3243779 | 0.90 | MEN1 (0.32) | KMT2AMEN1PLCG1ELANELMNA | |
| SCHEMBL3247087 | 0.90 | MEN1 (0.32) | KMT2AMEN1PLCG1ELANELMNA | |
| SCHEMBL3247082 | 0.90 | MEN1 (0.32) | KMT2AMEN1PLCG1ELANELMNA | |
| SCHEMBL3240637 | 0.86 | ALDH1A1 (0.38) | KMT2AMEN1MAPTPLCG1ELANE | |
| SCHEMBL3240641 | 0.86 | ALDH1A1 (0.38) | KMT2AMEN1MAPTPLCG1ELANE | |
| SCHEMBL7921168 | 0.86 | ALDH1A1 (0.38) | KMT2AMEN1MAPTPLCG1ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010056195-A1 | NEW COMPOUNDS 575 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | WO | disclosed |
| US-20100125087-A1 | NEW COMPOUNDS 575 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125087-A1 | NEW COMPOUNDS 575 | PSEN1, PSEN2, BACE1 | KMT2A 3888/4885MEN1 2423/4885MAPT 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.